GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (FRA:S1K) » Definitions » Cyclically Adjusted Book per Share

Predictive Oncology (FRA:S1K) Cyclically Adjusted Book per Share : €0.00 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Predictive Oncology Cyclically Adjusted Book per Share?

Note: As Cyclically Adjusted Book per Share is a main component used to calculate Cyclically Adjusted PB Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Predictive Oncology's adjusted book value per share for the three months ended in Mar. 2024 was €0.925. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.00 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 36.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 26.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Predictive Oncology was 36.80% per year. The lowest was 8.20% per year. And the median was 25.30% per year.

As of today (2024-06-25), Predictive Oncology's current stock price is €4.00. Predictive Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €0.00. Predictive Oncology's Cyclically Adjusted PB Ratio of today is .


Predictive Oncology Cyclically Adjusted Book per Share Historical Data

The historical data trend for Predictive Oncology's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Oncology Cyclically Adjusted Book per Share Chart

Predictive Oncology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,908.67 -2,919.67 -3,324.91 -1,751.08 -

Predictive Oncology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,205.49 -1,020.19 -1,477.30 - -

Competitive Comparison of Predictive Oncology's Cyclically Adjusted Book per Share

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Predictive Oncology's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Cyclically Adjusted PB Ratio falls into.



Predictive Oncology Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Predictive Oncology's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.925/131.7762*131.7762
=0.925

Current CPI (Mar. 2024) = 131.7762.

Predictive Oncology Quarterly Data

Book Value per Share CPI Adj_Book
201406 -4,022.034 100.560 -5,270.595
201409 -4,960.000 100.428 -6,508.257
201412 -7,214.516 99.070 -9,596.289
201503 -8,133.333 99.621 -10,758.561
201506 -8,293.939 100.684 -10,855.199
201509 4,964.423 100.392 6,516.416
201512 3,614.423 99.792 4,772.858
201603 212.864 100.470 279.191
201606 44.916 101.688 58.206
201609 0.588 101.861 0.761
201612 38.344 101.863 49.604
201703 114.730 102.862 146.980
201706 91.955 103.349 117.248
201709 61.425 104.136 77.729
201712 65.351 104.011 82.796
201803 71.654 105.290 89.679
201806 47.593 106.317 58.990
201809 38.707 106.507 47.891
201812 0.653 105.998 0.812
201903 0.703 107.251 0.864
201906 127.178 108.070 155.076
201909 119.214 108.329 145.017
201912 49.677 108.420 60.379
202003 31.911 108.902 38.614
202006 15.740 108.767 19.070
202009 12.521 109.815 15.025
202012 2.193 109.897 2.630
202103 12.238 111.754 14.431
202106 13.488 114.631 15.505
202109 12.410 115.734 14.130
202112 10.862 117.630 12.168
202203 10.244 121.301 11.129
202206 8.118 125.017 8.557
202209 7.624 125.227 8.023
202212 5.217 125.222 5.490
202303 4.364 127.348 4.516
202306 3.388 128.729 3.468
202309 2.706 129.860 2.746
202312 1.880 129.419 1.914
202403 0.925 131.776 0.925

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Predictive Oncology  (FRA:S1K) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Predictive Oncology Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Predictive Oncology (FRA:S1K) Business Description

Traded in Other Exchanges
Address
2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

Predictive Oncology (FRA:S1K) Headlines

No Headlines